Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2024-12-05 Audit Report / Informat…
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
Audit Report / Information Classification · 95% confidence The document is a formal resolution ('Gesellschafterbeschluss') from Heidelberg Pharma AG, acting as the sole shareholder of Heidelberg Pharma Research GmbH. The core content revolves around the subsidiary utilizing exemptions under German Commercial Code (§ 264 Abs. 3 HGB) regarding the preparation, auditing, and disclosure of its annual financial statements ('Jahresabschluss') for the fiscal year 2024. This decision relates directly to the formal accounting and reporting obligations, specifically concerning the annual financial statements and their exemption from standard procedures due to consolidation into the parent company's group accounts. This falls under the scope of formal audit/accounting information rather than the full Annual Report (10-K) or a general Audit Report (AR). Since it is a formal decision regarding the application of accounting principles and reporting requirements for the annual accounts, it aligns best with 'Audit Report / Information' (AR), which covers applied accounting principles and regulatory stress tests, as this document dictates how the annual accounts will be treated. FY 2024
2024-12-05 German
Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
Report Publication Announcement Classification · 99% confidence The document is a press release dated October 24, 2024, announcing that Heidelberg Pharma AG will participate in scientific and financial conferences in November 2024. It details the specific presentations, dates, and locations for events like 'World ADC San Diego 2024' and 'Deutsches Eigenkapitalforum'. This type of announcement, which informs investors about upcoming participation in investor/industry events, is best classified as an Investor Presentation (IP) announcement or, more broadly, a general corporate update related to investor relations activities. Since the document itself is an announcement *about* presentations rather than the presentation slides or a formal financial report (like 10-K or ER), and it is clearly focused on investor engagement, 'Investor Presentation' (IP) is the most fitting category, as it relates directly to the content being presented at these investor-focused forums. It is not a formal regulatory filing like 10-K or a standalone earnings release (ER).
2024-10-24 English
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Interim Management Statement on the First Nine Months of 2024' and provides detailed financial results, operational updates, and a financial outlook for the Heidelberg Pharma Group. While it contains a link to a 'complete set of figures' at the end, the document itself provides substantial financial data, including a table of key figures, income statements, and balance sheet summaries for the 9-month period. Therefore, it qualifies as an Interim/Quarterly Report (IR) rather than a mere announcement (RPA). 9M 2024
2024-10-10 English
Quartalsfinanzbericht
Interim / Quarterly Report Classification · 100% confidence The document is a '9-Monats-Finanzbericht' (9-month financial report) for Heidelberg Pharma AG, covering the period from December 1, 2023, to August 31, 2024. It contains detailed financial statements, including income, expenses, balance sheet data, and management's analysis of the financial results and outlook. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2024
2024-10-10 German
Q3 statement / Q3 financial report 2023/2024
Earnings Release Classification · 99% confidence The document is explicitly titled 'Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024' and reports on operational progress and financial figures for the period from December 1, 2023, to August 31, 2024 (9M 2024). This content structure—a comprehensive report covering a period shorter than a full fiscal year (nine months) and including detailed financial results, management commentary, and outlook adjustments—perfectly matches the definition of an Interim/Quarterly Report (IR). It is not a brief announcement (RPA) as the document is substantial (24,779 characters) and contains the full results discussion, not just a pointer to the report. 9M 2024
2024-10-10 English
Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Regulatory Filings Classification · 95% confidence The document is a press release dated October 1, 2024, announcing new clinical data for the drug candidate HDP-101 presented at the IMS 2024 meeting. It details study results (complete remission in one patient) and announces a subsequent R&D webinar for investors and analysts. This content focuses on specific scientific/clinical updates and results, which is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full quarterly/annual report (10-K or IR), nor a formal transcript (CT), and it is primarily focused on presenting key results and updates rather than just announcing the publication of a report (RPA), the most fitting category is Earnings Release (ER), as clinical trial updates often accompany or substitute for traditional earnings highlights in biotech/pharma. However, given the focus is purely on study results and not comprehensive financial performance for a period, it aligns closely with an announcement of key operational/scientific results. If 'ER' is interpreted strictly as financial earnings, then 'RNS' (Regulatory Filings/General Announcement) might be considered. But in the context of corporate news dissemination, clinical trial updates announcing significant results are often grouped with ERs. Given the structure and content (key results, future webinar), ER is the best fit among the specific operational/financial categories, though RNS is a strong fallback. I will classify it as ER as it reports on key operational performance indicators (clinical trial success).
2024-10-01 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.